#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize cannabinoid hyperemesis syndrome as a distinct clinical entity characterized by paradoxical nausea and vomiting in chronic cannabis users, as it requires cessation of cannabis rather than standard antiemetic treatments. This diagnosis prevents unnecessary diagnostic workup and inappropriate medication in patients whose symptoms will resolve only with cannabis discontinuation. Understanding this syndrome is critical for counseling patients about cannabis risks and for identifying a reversible cause of refractory nausea that affects an increasing number of patients as cannabis use becomes more prevalent and potent.
Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which chronic cannabis use, despite cannabis’s antiemetic properties at lower doses, triggers severe cyclic vomiting and abdominal pain that typically resolves only with cessation of use. The syndrome reflects cannabis’s biphasic pharmacological effects, wherein THC demonstrates dose-dependent and potentially paradoxical responses that differ from its well-known antiemetic action at therapeutic doses. Clinicians must recognize CHS as a diagnosis of exclusion after ruling out structural, metabolic, and infectious causes of refractory nausea and vomiting, as delayed diagnosis can result in unnecessary testing and prolonged patient suffering. The typical presentation includes heavy, chronic cannabis use followed by repeated episodes of intractable vomiting that paradoxically improve with hot showers or baths, along with compulsive bathing behavior. Recognition of this syndrome is increasingly important as cannabis potency and consumption patterns have evolved, particularly among younger patients and those using high-THC products. Clinicians should maintain a high index of suspicion for CHS in patients with chronic cannabis use presenting with unexplained cyclic emesis and counsel patients that complete abstinence from cannabis remains the only definitive therapeutic intervention.
“Cannabinoid hyperemesis syndrome represents a real clinical entity we’re seeing more frequently, but it remains fundamentally a diagnosis of exclusion that requires ruling out organic pathology first. The biphasic dose-response relationship with THC is biologically plausible and supported by case reports and clinical observation, though we lack large prospective studies that would let us define incidence, risk factors, and predictive biomarkers with confidence.”
🤢 Cannabinoid hyperemesis syndrome (CHS) presents a clinical paradox that warrants careful consideration in patients with recurrent nausea and vomiting, particularly as cannabis use becomes more prevalent and potent. The syndrome’s biphasic dose-response relationship—where low doses produce antiemetic effects while high doses trigger severe emesis—underscores the importance of detailed substance use history, including frequency, potency, and route of administration, rather than simply documenting cannabis use as present or absent. Clinicians should recognize that CHS remains a diagnosis of exclusion, requiring investigation for other organic causes of hyperemesis such as gastroparesis, cyclic vomiting disorder, and gastrointestinal obstruction before attributing symptoms to cannabis alone. The dramatic response to cessation of cannabis use and, paradoxically, hot showers during acute episodes can serve as diagnostic clues, though patients may not spontane
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Read next
